Contact
searchSearch
HMP Global
Login

News

Alexander E Perl, MD, MS
Videos
Evaluating the 7+3 Regimen in Frontline Acute Myeloid Leukemia Treatment
03/17/2026
Alexander E. Perl, MD
At the 2026 LL&M Winter Symposium, Alexander E Perl, MD, MS, presented the latest evolving data on the commonly utilized 7+3 regimen for patients with newly diagnosed acute myeloid leukemia.
At the 2026 LL&M Winter Symposium, Alexander E Perl, MD, MS, presented the latest evolving data on the commonly utilized 7+3 regimen for patients with newly diagnosed acute myeloid leukemia.
At the 2026 LL&M Winter...
03/17/2026
Oncology
Christopher Hourigan, MD, PhD
Videos
The Expanding Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia
03/13/2026
Christopher Hourigan, DM, DPhil, FRCP
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD, reviews the most recent high-impact developments in measurable residual disease (MRD) testing in acute myeloid leukemia, focusing on key updates from recent months.
Christopher Hourigan, MD, PhD,...
03/13/2026
Oncology
News
Dapolsertib Well-Tolerated, Demonstrates Clinical Activity in Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a...
03/02/2026
Oncology
Ira Zackon, MD
Videos
Real-World Analysis Finds Venetoclax-Based Induction Effective for Very Elderly Patients With Acute Myeloid Leukemia
03/02/2026
Ira Zackon, MD
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results from a large real-world analysis which found venetoclax plus a hypomethylating agent is a feasible and effective therapeutic option for patients with AML aged 70 years and older.
Ira Zackon, MD, shared results...
03/02/2026
Oncology
Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for Relapsed/Refractory Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with relapsed/refractory...
The combination of venetoclax...
01/12/2026
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology
News
Autologous Stem Cell Transplantation Shows Improved Relapse-Free Survival Benefit Over Chemotherapy for AML Consolidation Therapy
12/01/2025
Emily Estrada
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute...
12/01/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use